Management of paroxysmal atrial fibrillation

Lip, G Y H; Metcalfe, M. J.; RAE, A.P.

doi:10.1093/qjmed/86.8.467

Cited by 21 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AF can have adverse consequences related to a reduction in cardiac output and to atrial and atrial appendage thrombus formation that can lead to systemic embolization [4][5][6][7] . The choice of therapy is influenced by whether the AF is recurrent paroxysmal, recurrent persistent, or permanent (chronic) as defined above 1 .…”

Section: Discussionmentioning

confidence: 99%

A Case of Refractory Atrial Fibrillation Treated with Amiodarone

Alam

Karmaker

Ara³

et al. 2013

Bangla J Med

View full text Add to dashboard Cite

We report a case of atrial fibrillation (AF) of unknown duration with fast ventricular rate which was refractory to intravenous (i.v.) digoxin, verapamil and DC (direct current) shock regarding rate control. Amiodarone was given in bolus & then in maintenance dose which ultimately controlled the rate and finally converted into sinus rhythm. DOI: http://dx.doi.org/10.3329/bjmed.v21i2.13622 Bangladesh J Medicine 2010; 21: 108-110

show abstract

Section: Discussionmentioning

confidence: 99%

A Case of Refractory Atrial Fibrillation Treated with Amiodarone

Alam

Karmaker

Ara³

et al. 2013

Bangla J Med

View full text Add to dashboard Cite

show abstract

“…Flecainide is also proven to reduce symptoms, but there are doubts about its safety. In a review on this subject, Lip et al (32) recommended starting therapy with sotalol, using either quinidine or propafenone as second line treatment. Amiodarone is especially useful for resistant cases and may be effective in low doses thereby reducing the risks of toxicity.…”

Section: Paroxysmal Atrial Fibrillationmentioning

confidence: 99%

The causes and management of atrial fibrillation

Rudd¹,

Maxwell²,

Kendall³

1996

J Clin Pharm Ther

View full text Add to dashboard Cite

Atrial fibrillation is present in approximately 10% of the population aged over 65 years, in whom its presence is associated with a significantly increased morbidity and mortality. Principal complications include reduced cardiac output and the precipitation of heart failure and thromboembolic phenomena, including strokes and peripheral emboli. In the majority of cases atrial fibrillation is associated with ischaemic heart-disease and hypertension. Other important causes are thyrotoxicosis, valvular heart-disease and atrial septal defect.The primary aims of treatment in atrial fibrillation are to terminate the arrhythmia (cardioversion) with either drugs or direct current (DC) shock and to prevent its recurrence. Effective cardioversion may necessitate the treatment of underlying pathology. If these primary aims cannot be achieved then an attempt must be made to effectively control the ventricular rate with drugs such as digoxin. Recently, further strong evidence has been provided to support the role of anticoagulants and antiplatelet drugs in preventing the major problem of systemic thromboembolic complications. Some of the special difficulties relating to the treatment of atrial fibrillation associated with thyrotoxicosis as well as paroxysmal atrial fibrillation will also be considered.

show abstract

“…22,23 Atrial fibrillation, the most common cardiac arrhythmia, can have adverse consequences related to a reduction in cardiac output and to atrial appendage thrombus formation. [23][24][25] Affected patients may be at increased risk of death. In a study in patients with self-reported major medical illnesses (liver or kidney disease, rheumatoid arthritis, multiple sclerosis, heart failure, hemorrhagic stroke, and arterial thrombosis), the risk of venous thrombosis was increased, with odds ratios in the range 1.5 to 4.9.…”

Section: Introductionmentioning

confidence: 99%

Influence of Prescribed Blood Products on the Incidence of Deep Vein Thrombosis and Pulmonary Embolism in Surgical Patients

Marušič

Locatelli

Mrhar

et al. 2017

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Deep vein thrombosis (DVT) and pulmonary embolisms (PEs) are common complications after surgical procedures. The influence of prescribed blood products on the occurrence of DVT and PE was evaluated in postsurgical patients in this retrospective case-control study. The records of 286 surgical patients were analyzed: DVT (n = 52), PE (n = 92), and a control group (n = 142). The amounts of prescribed blood, blood products, and vitamin K were reviewed, together with appropriate prescribing of low-molecular-weight heparins. The influence of prescribed blood products on the occurrence of DVT or PE was analyzed using multinomial logistic regression. We demonstrated a significant difference between the test and control groups ( P < .05) in relation to receiving packed red blood cells. Treatment with red blood cells was associated with an increased risk of PE but not DVT. Patients who developed PE after surgery were hospitalized for longer (median 10 days) than patients with DVT (median 6 days). There was no difference between the test and control groups concerning treatment with fresh frozen plasma. Inadequate thromboprophylaxis significantly increased the likelihood of DVT. There is a connection between receiving packed red blood cells and occurrence of postoperative PE in surgical patients. Thus, patients receiving red blood cells should be monitored more closely after surgery, as they are more likely to develop PE postoperatively.

show abstract

Management of paroxysmal atrial fibrillation

Cited by 21 publications

References 0 publications

A Case of Refractory Atrial Fibrillation Treated with Amiodarone

A Case of Refractory Atrial Fibrillation Treated with Amiodarone

The causes and management of atrial fibrillation

Influence of Prescribed Blood Products on the Incidence of Deep Vein Thrombosis and Pulmonary Embolism in Surgical Patients

Contact Info

Product

Resources

About